Acoramidis hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for acoramidis hydrochloride and what is the scope of patent protection?
Acoramidis hydrochloride
is the generic ingredient in one branded drug marketed by Bridgebio Pharma and is included in one NDA. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Acoramidis hydrochloride has one hundred and eighteen patent family members in thirty-four countries.
One supplier is listed for this compound.
Summary for acoramidis hydrochloride
| International Patents: | 118 |
| US Patents: | 13 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 9 |
| Patent Applications: | 20 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for acoramidis hydrochloride |
| What excipients (inactive ingredients) are in acoramidis hydrochloride? | acoramidis hydrochloride excipients list |
| DailyMed Link: | acoramidis hydrochloride at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for acoramidis hydrochloride
Generic Entry Date for acoramidis hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for acoramidis hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bayer | PHASE4 |
| Eidos Therapeutics, a BridgeBio company | PHASE3 |
| Alexion Pharmaceuticals | Phase 1 |
Pharmacology for acoramidis hydrochloride
| Drug Class | Transthyretin Stabilizer |
| Mechanism of Action | Cytochrome P450 2C9 Inhibitors Transthyretin Stabilizers |
Anatomical Therapeutic Chemical (ATC) Classes for acoramidis hydrochloride
US Patents and Regulatory Information for acoramidis hydrochloride
International Patents for acoramidis hydrochloride
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Africa | 202407964 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF | ⤷ Start Trial |
| Poland | 3836920 | ⤷ Start Trial | |
| Eurasian Patent Organization | 202092272 | СПОСОБЫ ЛЕЧЕНИЯ ТРАНСТИРЕТИНОВОГО АМИЛОИДОЗА С ПРИМЕНЕНИЕМ AG10 | ⤷ Start Trial |
| South Korea | 20250151621 | AG-10, 이의 중간체, 및 이의 염을 제조하는 방법 (AG-10 PROCESSES FOR PREPARING AG-10 ITS INTERMEDIATES AND SALTS THEREOF) | ⤷ Start Trial |
| Japan | 2021518381 | ⤷ Start Trial | |
| San Marino | T202500463 | ⤷ Start Trial | |
| Portugal | 3836920 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for acoramidis hydrochloride
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2934514 | CA 2025 00013 | Denmark | ⤷ Start Trial | PRODUCT NAME: ACORAMIDIS, AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY ACORAMIDIS HYDROCHLORIDE; REG. NO/DATE: EU/1/24/1906 20250211 |
| 2934514 | 2590011-9 | Sweden | ⤷ Start Trial | PRODUCT NAME: ACORAMIDIS, AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY ACORAMIDIS HYDROCHLORIDE; REG. NO/DATE: EU/1/24/1906 20250211 |
| 2934514 | C20250016 | Finland | ⤷ Start Trial | |
| 2934514 | 122025000014 | Germany | ⤷ Start Trial | PRODUCT NAME: ACORAMIDIS ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ HIERVON; REGISTRATION NO/DATE: EU/1/24/1906 20250210 |
| 2934514 | 301323 | Netherlands | ⤷ Start Trial | PRODUCT NAME: ACORAMIDIS EN/OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER ACORAMIDISHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/24/1906 20250211 |
| 2934514 | LUC50002 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: ACORAMIDIS, ET/OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE CHLORHYDRATE D'ACORAMIDIS; AUTHORISATION NUMBER AND DATE: EU/1/24/1906 20250210 |
| 2934514 | PA2025512 | Lithuania | ⤷ Start Trial | PRODUCT NAME: AKORAMIDIS IR/ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPACAKORAMIDZIO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/24/1906 20250210 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch